Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
KRRO 
Frequency Therapeutics Inc (KRRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: KRRO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $8.67
1 Year Target Price $8.67
| 6 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.52% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 74.49M USD | Price to earnings Ratio - | 1Y Target Price 8.67 |
Price to earnings Ratio - | 1Y Target Price 8.67 | ||
Volume (30-day avg) 10 | Beta 2.87 | 52 Weeks Range 5.20 - 55.89 | Updated Date 12/18/2025 |
52 Weeks Range 5.20 - 55.89 | Updated Date 12/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.42 |
Earnings Date
Report Date 2025-11-18 | When - | Estimate -2.6775 | Actual -1.92 |
Profitability
Profit Margin - | Operating Margin (TTM) -1764.86% |
Management Effectiveness
Return on Assets (TTM) -29.16% | Return on Equity (TTM) -63.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 26679803 | Price to Sales(TTM) 10.11 |
Enterprise Value 26679803 | Price to Sales(TTM) 10.11 | ||
Enterprise Value to Revenue 3.62 | Enterprise Value to EBITDA -5.6 | Shares Outstanding 9417295 | Shares Floating 5778546 |
Shares Outstanding 9417295 | Shares Floating 5778546 | ||
Percent Insiders 6.16 | Percent Institutions 104.21 |
About Frequency Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2023-11-06 | CEO, President, Interim CFO, Principal Financial Officer & Director Dr. Ram Aiyar MBA, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 87 | Website https://www.korrobio.com |
Full time employees 87 | Website https://www.korrobio.com | ||
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.